Background Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to regulate inflammatory mediators. The Work Limitations Questionnaire (WLQ) is a reliable tool for assessing work productivity in patients with chronic health conditions. PALACE 1 compared the efficacy and safety of APR with placebo (PBO) in patients with active psoriatic arthritis (PsA) despite prior conventional disease-modifying antirheumatic drugs (DMARDs) and/or biologics. Objectives Assess the effect of APR on work productivity and work limitations in the PALACE 1 study. Methods Patients were randomized 1:1:1 to PBO, APR 20 mg BID (APR20), or APR 30 mg BID (APR30) stratified by baseline DMARD use (yes/no), and treated for 16 weeks to reach the primary end point. Patients completed the WLQ, a 25-item questionnaire that assesses the impact of chronic health conditions on work performance and productivity, at baseline and Week 16. Work limitations were categorized into 4 domains: physical demands (PDS), mental demands (MDS), time management demands (TMS), and output demands (ODS), which were then used to calculate the WLQ index. Results 504 patients were randomized in PALACE 1. Of the 261 patients who completed the WLQ, baseline work productivity and work limitations were similar across treatment groups. At Week 16, APR20 and APR30, vs. placebo, were associated with a greater mean change from baseline in PDS (-5.58 and -6.24 vs. -2.14), MDS (-2.22 and -5.18 vs. 1.15), TMS (-4.03 and -8.76 vs. -4.25), and ODS (-5.92 and -10.3 vs. -1.34), resulting in a greater mean improvement in the WLQ index (-0.01 and -0.03 vs. 0.00), which corresponds to a higher median percent improvement of productivity loss (18.9% and 24.7% vs. -3.7%). Higher productivity improvements were also observed among APR20 and APR30 ACR20 responders at Week 16 – PDS (-11.8 and -7.61), MDS (-8.56 and -11.0), TMS (-7.88 and -15.8), and ODS (-10.6 and -20.1) – resulting in a higher mean improvement in the WLQ index (-0.03 and -0.05), which corresponds to a higher median percent improvement in work productivity (57.9% and 46.8%). Conclusions APR20 and APR30 increased work productivity and improved work limitations compared with PBO in patients with active PsA despite prior conventional disease-modifying antirheumatic drugs (DMARDs) and/or biologics. Disclosure of Interest F. Zhang Employee of: Celgene Corporation, T. Tencer Employee of: Celgene Corporation, S. Li Employee of: Celgene Corporation DOI 10.1136/annrheumdis-2014-eular.4419
BackgroundApremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to regulate inflammatory mediators. The Work Limitations Questionnaire (WLQ) is a reliable tool for assessing limitations on work productivity in patients with chronic health conditions. The PALACE 1, 2, and 3 trials compared the efficacy and safety of APR with placebo in patients with active psoriatic arthritis (PsA) despite prior conventional disease-modifying antirheumatic drugs (DMARDs) and/or biologics.ObjectivesAssess the effect of APR on work productivity and work limitations over 52 weeks in a pooled analysis.MethodsPatients were randomized (1:1:1) to receive placebo, APR 20 mg BID (APR20), or APR 30 mg BID (APR30). Patients whose swollen and tender joint counts had not improved ≥20% at Week 16 were considered non-responders and were required to be re-randomized (1:1) to APR20 or APR30 if initially randomized to placebo, or continued on their initial APR dose. At Week 24, all patients remaining on placebo were re-randomized to APR20 or APR30. Treatment efficacy at Week 16 was analyzed based on the intent-to-treat population, and analyses at Week 52 and Week 104 were based on data as observed. The WLQ, a 25-item questionnaire that assesses the impact of chronic health conditions on work performance and productivity, was administered at baseline, Week 16, and Week 52. Work limitations were categorized into 4 domains: physical demands (PDS), mental demands (MDS), time management demands (TMS), and output demands (ODS), which were then used to calculate the WLQ index.ResultsFor the patients who completed the WLQ, baseline work productivity and work limitations were similar across treatment groups. At Week 16, APR20 and APR30, vs. placebo, were associated with a greater mean change from baseline in PDS, MDS, TMS, and ODS, resulting in a greater mean improvement in the WLQ index (Table), which corresponds to a higher mean percent improvement of productivity loss. Productivity improvements in PDS, MDS, TMS, and ODS were also maintained among patients receiving APR20 and APR30 at Week 52 (Table).ConclusionsAPR20 and APR30 treatment increased work productivity and improved work limitations among patients with active PsA who were not adequately controlled with prior or concurrent conventional DMARDs and/or prior biologics. Improvements in productivity loss were maintained at Week 52 of treatment.Disclosure of InterestF. Zhang Employee of: Celgene Corporation, Z. Clancy Employee of: Celgene Corporation, S. Li Employee of: Celgene Corporation
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.